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Human milk oligosaccharides (HMOs) enrich beneficial bifidobacteria in the infant
gut microbiome which produce molecules that impact development and physiology.
2′fucosyllactose (2′FL) is a highly abundant fucosylated HMO which is utilized
by Bifidobacterium longum subsp. infantis, despite limited scientific understanding
of the underlying mechanism. Moreover, there is not a current consensus on
whether free fucose could be metabolized when not incorporated in a larger
oligosaccharide structure. Based on metabolic and genomic analyses, we hypothesize
that B. infantis catabolizes both free fucose and fucosyl oligosaccharide residues to
produce 1,2-propanediol (1,2-PD). Accordingly, systems-level approaches including
transcriptomics and proteomics support this metabolic path. Co-fermentation of fucose
and limiting lactose or glucose was found to promote significantly higher biomass and
1,2-PD concentrations than individual substrates, suggesting a synergistic effect. In
addition, and during growth on 2′FL, B. infantis achieves significantly higher biomass
corresponding to increased 1,2-PD. These findings support a singular fucose catabolic
pathway in B. infantis that is active on both free and HMO-derived fucose and intimately
linked with central metabolism. The impact of fucose and 2′FL metabolism on B. infantis
physiology provides insight into the role of fucosylated HMOs in influencing host- and
microbe-microbe interactions within the infant gut microbiome.
Keywords: bifidobacteria, human milk oligosaccharides, fucose, 2′fucosyllactose, microbiota, microbiome
INTRODUCTION
Human milk nourishes infants and contains host-indigestible human milk oligosaccharides
(HMOs) in addition to bioavailable nutrients. These compounds contribute to overall infant
nutrition by shifting gut microbiome composition to favor beneficial microbiota that metabolize
HMOs to bioactive products (1–5). Despite incorporating the same monosaccharide building
blocks, HMOs vary structurally at the level of primary sequence and are diversified by degree of
polymerization, branching, and secondary modifications such as fucosylation (6). 2′ Fucosyllactose
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(2′FL) is the most abundant fucosylated HMO and accounts
for up to 30% of total HMOs in secretor women (6, 7). 2′FL
has been designated generally recognized as safe by the U.S.
Food and Drug Administration as well as obtaining similar
status by other regulatory agencies. As a consequence, it is
added to commercial infant formula to more closely mimic the
composition of human milk.
Bifidobacterium longum subsp. infantis (B. infantis) is often
the dominant microbe in the infant gut microbiome where it
utilizes fucosylated HMOs such as 2′FL. Several studies report
that B. infantis utilizes 2′FL as a sole carbohydrate source (8–
11). The metabolic fate of the fucosyl moiety of 2′FL, however,
remains uncertain in its intracellular catabolism. Mechanistic
hypotheses based solely on genomics are hindered due to the
absence of identifiable fucose-active genes. Specifically, B. infantis
lacks the full complement of the canonical pathway genes
possessed by other bacteria such as Escherichia coli (12–14). This
catabolic pathway results in the production of 1,2-propanediol
(1,2-PD) through a series of phosphorylated intermediates (15,
16). Briefly, the pathway is regulated by fucR and relies on a
fucose permease (fucP) to import fucose intracellularly where
it is subsequently catabolized. Fucose isomerase (fucI) converts
L-fucose to L-fuculose, which is subsequently phosphorylated
by fucose kinase (fucK). L-fuconate-1-phosphate is converted
to dihydroxyacetone phosphate and lactaldehyde by an aldolase
(fucA). Dihydroxyacetone phosphate can subsequently be
shunted to the central glycolytic pathway and lactaldehyde
converted to 1,2-PD by an oxidoreductase (fucO) under
anaerobic conditions (17). B. infantis ATCC 15697T lacks
the majority of homologous genes predicted in this pathway,
although the genome encodes fucO which could produce 1,2-PD
from lactaldehyde. Despite this, B. infantis has been previously
observed to metabolize free fucose and produces 1,2-PD in co-
fermentation with a low concentration of glucose (14).
Other bacteria such as Xanthomonas campestris
and Campylobacter jejuni catabolize fucose through
phosphorylation-independent pathways to produce lactate
as an end product rather than 1,2-PD (12, 13) Moreover,
Sphingomonas sp. metabolizes rhamnose, an isomer of fucose, to
produce lactadehyde and pyruvate (18). The pathway requires
a permease prior to intracellular conversion of fucose to
fuconolactone by fucose dehydrogenase, and then hydrolyzed to
form fuconate by fuconolactone hydrolase. Fuconate dehydratase
then catalyzes the production of 2-keto-3-deoxy-fuconate, which
is further dehydrogenated to 2,4-diketo-3-deoxy-fuconate. The
metabolic fate of 2,4-diketo-3-deoxy-fuconate diverges in that
X. campestris produces lactate and pyruvate by a hydrolysis
reaction whereas Sphingomonas sp. produces lactaldehyde and
pyruvate by an aldol reaction. Homologous genes to those used
in these pathways are identifiable in the B. infantis genome. The
presence of these putative fucose genes informed a hypothetical
bifidobacterial fucose metabolic pathway in B. infantis and other
infant-associated bifidobacteria (11, 14).
Studies of bifidobacterial fucose metabolism have generally
focused on fucosylated HMOs such as 2′FL. Identification
of homologous genes, functional genomic analyses such as
transcriptomics, and quantitation of metabolic end products
1,2-PD and short-chain fatty acids have heretofore provided the
primary evidence for the bifidobacterial fucose metabolic
pathway (11, 14, 19). Thus the mechanism underlying
bifidobacterial fucose metabolism remains hypothetical in
the absence of direct observation of metabolic intermediates
and loss-of-function genetic perturbations. Furthermore, B.
infantis growth on free fucose as a sole carbohydrate source
is incompletely characterized as existing studies focus on
demonstrating B. infantis growth on free fucose or in co-
fermentation (14, 20–22). As such, much uncertainty remains in
the path by which B. infantis utilizes fucose as a free product or
integrated into HMOs.
This study investigates B. infantis utilization of 2′FL-derived
and free fucose as well as the impact of carbohydrate source
and concentration on fucose metabolism. In order to explicate B.
infantis physiology while metabolizing fucose, our experimental
system quantifies growth kinetics, secreted end products, the
proteome, and transcriptome. As a consequence, an integrated
systems-level resolution of B. infantis utilization of 2′FL and
fucose is presented herein.
MATERIALS AND METHODS
Bacterial Strains and Propagation
B. longum subsp. infantis strain ATCC 15697T (originally isolated
from human infant feces) was used in this study. Propagation
was performed in de Mann, Rogosa and Sharpe (MRS; BD
Difco, USA) supplemented with 0.05% (wt/vol) L-cysteine
hydrochloride (Sigma-Aldrich, USA) at 37◦C under anaerobic
conditions (7% H2, 10% CO2, N2 balance) (Coy Lab, USA).
Microplate Growth Assay
Growth phenotypes were analyzed in a 96-well format using a
PowerWave HT Microplate Spectrophotometer (BioTek, USA).
Overnight cultures were inoculated 1% (vol/vol) to modified
MRS media (mMRS) that contains a defined carbohydrate
substrate without acetate and Tween80. Carbohydrates include
glucose, lactose, galactose, (Sigma-Aldrich, USA), fucose (Chem-
Impex, USA), 2′fucosyllactose (BASF, Germany), and mixtures
thereof at varying final concentrations (wt/vol) as the sole
carbohydrate source(s). The growth assay was conducted
anaerobically at 37◦C until bacterial growth as measured by
optical density at 600 nm (OD600) reached stationary phase. Each
carbohydrate source or mixture of sources were evaluated in
biological triplicates with three technical replicates. Inoculated
mMRS without carbohydrate served as the negative control,
and inoculated mMRS with 2% (wt/vol) lactose served as the
positive control. Bacterial growth kinetics were calculated using
Wolfram Mathematica with the equation described by Dai








1OD corresponds to the adjusted optical density, 1ODasym the
optical density at stationary phase, k the growth rate, and tc
the time to reach maximum growth rate (23). The growth assay
was performed for 72 h at 37◦C under anaerobic conditions
by shaking for 5 s and assessing OD600 at 15-min intervals
with triplicate biological and technical replicates of each broth
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composition. At critical points during bacterial fermentation,
three technical replicates were selected at random and reserved
for intracellular metabolite analysis.
Bacterial metabolism was quenched with a solution of 900
µL 60% methanol (Thermo Fisher Scientific, USA) with 0.65%
(w/v) ammonium carbonate (Honeywell, USA) at −20◦C added
to 300 µL cell-free growth media (24, 25) The solution was
thoroughly mixed and incubated 30min at −20◦C prior to
pelleting cells and reserving supernatant. Cell pellet was washed
with 900 µL methanol/ammonium carbonate solution at−20◦C.
Supernatant was reserved and diluted with 900 µL HPLC-
grade water (Thermo Fisher Scientific, Waltham, MA) at 4◦C.
Supernatant solution was thoroughly mixed prior to storage at
−80◦C. Reserved pellets were resuspended in 500 µL methanol
with 24mg/L adonitol (Sigma-Aldrich, St. Louis, MO) and stored
at−80◦C.
Growth Inhibition Assay
Overnight cultures were inoculated 1% (vol/vol) to MRS
supplemented with 0.05% (wt/vol) L-cysteine hydrochloride
(Sigma-Aldrich, USA) modified with added 1,2-PD, lactate,
or phosphate-buffered saline. Each condition was evaluated in
biological triplicate. Lactate was used as a control as it is
known to inhibit B. infantis growth. MRS and equal volumes
of phosphate-buffered saline served as additional controls. 1,2-
PD concentration ranged from 0.08 to 168mM and lactate
concentration ranged between 0.07 to 144mM. Cultures were
grown anaerobically at 37◦C for 24 h after which bacterial growth
was measured by OD600. Inhibition was determined using a
comparison of the final OD600 at each concentration as compared
to other concentrations and controls.
Characterization of Microbial Metabolic
Intermediate and End Products
Bacterial growth for metabolic profiling was performed in 15
replicates of 2mL mMRS inoculated at a concentration of 1%
(v/v) and incubated for 48 h at 37◦C under anaerobic conditions.
OD600 was assessed using a NanoDrop spectrophotometer
(Thermo Fisher Scientific, USA). Harvested cells were pelleted,
washed with 1.5mL 1× phosphate-buffered saline (PBS), and
resuspended in 1mL RNAlater (Sigma-Aldrich, St. Louis, MO).
Cells resuspended in RNAlater were incubated for 8 h at 4◦C
prior to storage at −80◦C. Cell-free spent growth media (500
µL) was reserved and quenched as described above and stored
at−80◦C.
Intracellular metabolites were extracted and derivatized for
GC-MS analysis. Suspended pellets were thawed to −20◦C,
transferred to 2mL tubes containing 600mg 100µm diameter
silica lysis matrix (OPS Diagnostics, USA), and subjected to
bead beating (3 ×{40 s at 6.0 m/s followed by 5min incubation
at −20◦C}) using a FastPrep 24 bead beater (MP Biomedicals,
USA). Whole-cell lysate was transferred to a 2mL Safe-Lock
tube (Eppendorf, USA) and lysing matrix was washed with 500
µL methanol. 1mL chloroform (Thermo Fisher Scientific, USA)
was added to the pooled whole-cell lysate and methanol wash
and vortexed 2min. Samples were incubated 4 h at −20◦C and
vortexed for 1min at 1-hour intervals. Debris was pelleted at
21,200 × g for 5min in a 4◦C rotor, supernatant was transferred
to a clean 2mL Safe-Lock tube and dried overnight using a
Vacufuge (Eppendorf, USA) in V-AL mode at room temperature
with rotation. Dried extracts were derivatized following a
modified protocol (25, 26). 20µL pyridine (Sigma-Aldrich, USA)
with 20 mg/mL methoxyamine hydrochloride (Sigma-Aldrich,
USA) was added to dried extracts and vortexed 2min prior
to 90min incubation at 32◦C with continuous mixing. Thirty-
two µL N-methayl-N-(trimethylsilyl)trifluoroacetamide (Sigma-
Aldrich, USA) was added and samples were vortexed 2min prior
to incubation (30min at 37◦C, 60min at 32◦C, and 60min at
room temperature) with constant mixing. Debris was pelleted at
17,000 × g for 5min. 50 µL supernatant was transferred to a
vial insert and stored at −80◦C overnight prior to measurement.
24 mg/L standards (pyruvate, lactate, 1,2-propanediol, L-fucono-
1,4-lactone) (Sigma-Aldrich, USA) in methanol were derivatized
following the above protocol. GC-MS analysis was performed at
the University of Massachusetts Mass Spectrometry Center using
an Agilent 6890/5973 GC- MS (Agilent Technologies, USA).
In summary, 1 µL of the derivatized sample was injected in
split mode (10:1). Gas chromatography was performed on a
30m, 0.25mm, 0.25µm film thickness DB-5ms column (J&W
Scientific, USA) using 1.2mL min−1 helium flow. Ionization of
analytes was done by electron ionization (EI +) at 70 eV. After
2min at 70◦C, the temperature was increased to 200◦C at 12◦C
s−1, then to 250◦C at 8◦C s−1, and to 325◦C at 12◦C s−1, followed
by an additional constant temperature period of 5min at 325◦C.
The transfer line temperature was set to 290◦C. Full scan mass
spectra were obtained from 45 to 600 m/z with 2 scans s−1 and
a solvent delay time of 4min. Compounds were identified using
Agilent MSD ChemStation Software (Version E02.02, Agilent
Technologies, USA) and NIST Spectral Search Program with
NIST Standard Reference Database (Version 2.2, NIST, USA).
Extracellular metabolites were quantitated by HPLC. One
mL quenched cell-free spent growth media concentrated
using a Vacufuge for 4 h in V-AL mode at room temperature
with rotation. Dehydrated solutes were resuspended in 200
µL HPLC-grade water and filtered through a 0.22-µm filter
(Sartorius, USA) and stored at −80◦C until analysis. Metabolite
(2′fucosyllactose, fucose, lactose, glucose, 1,2-propanediol,
acetate, lactate, and formate) concentrations were quantified
using an 1260 Infinity HPLC system (Agilent Technologies,
USA) equipped with a Optilab T-rEX refractive-index detector
(Wyatt Technology, USA). Separation was performed using an
Aminex HPX-87H column (ID 7.8mm by 300mm; Bio-Rad
Laboratories, USA) at 30◦C in a mobile phase of 5mM H2SO4
with a flow rate of 0.6 mL/min and an injection volume of
20 µL. Analytical standards of 2′FL (BASF, Germany), fucose,
lactose, glucose, organic acids (Sigma-Aldrich, USA), and
1,2-propanediol (Alfa Aesar, USA) were used to generate a
standard curve from seven concentrations. Each measurement
was performed in duplicate.
Proteome Sample Preparation
Cultures were harvested at mid-exponential phase and the pellet
was washed 3X with PBS buffer and stored at −80◦C until
subsequent analysis. Cell pellets were suspended in 1X SDS lysis
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and solubilization buffer (Protifi LLC, USA) and were sonicated
with Bioruptor pico (Diagenode, USA) at high power for 10–
15min (sonication cycle: 30 s ON, 30 s OFF). The cell lysate
was clarified by centrifugation at 13,000 g for 8min. Protein
concentrations were measured using the Pierce BCA protein
Assay kit (Thermo Fisher Scientific, USA) on a Nanodrop
spectrophotometer. Sample preparation for mass spectrometry
was performed using the S-Trap micro universal MS sample
prep kit (Protifi LLC, USA). Samples were reduced, alkylated,
and trypsin digested according to manufacturer instructions.
Briefly, 30–40 µg protein was loaded on S-Trap micro spin
columns and washed with wash buffer. Each sample was
mixed with digestion buffer containing mass spectrometry grade
trypsin (Promega, USA) at a 1:50 ratio (wt/wt) and was added
directly to the micro spin column. Samples were incubated in
a water bath at 47◦C for 1 h followed by overnight incubation
at 37◦C. Peptides were eluted by serial additions of 50mM
TEAB, 0.2% formate, and 0.2% formate in 50% acetonitrile.
Eluted peptides were pooled and evaporated in a Vacufuge to
dehydration and stored at −80◦C until subsequent analysis.
Tryptic peptides were purified with ZIPTIP R© C18 pipette tips
(MerckMillipore, USA) as permanufacturer instructions prior to
MS/MS analysis.
Mass Spectrometry Proteomics
Tryptic digests were analyzed using a Thermo Easy-nLC 1000
nanoLC system coupled to a Thermo Orbitrap Fusion mass
spectrometer (Thermo Fisher Scientific, USA). Peptides were
separated using a 90-min gradient of increasing concentration of
acetonitrile and infused into themass spectrometer at 300 nl/min.
MS1 data was acquired at 60,000 resolution in the Orbitrap
and MS/MS data were acquired in a data-dependent manner
selecting the top five most intense ions for fragmentation, using
a nominal CID collision energy of 35%. Data were processed
using Proteome Discoverer 2.0 (Thermo Fisher Scientific, USA).
MS/MS data was queried against a database constructed from the
UniProt database (www.uniprot.org) containing Bifidobacterium
longum subsp. infantis ATCC 15697 (https://www.uniprot.
org/proteomes/UP000001360, Proteome ID: UP000001360).
Proteomes were analyzed using SEQUEST (27). Proteome
Discoverer 2.3.0.523 (Thermo Fisher Scientific, USA). SEQUEST
was searched with a fragment ion mass tolerance of 0.60 Da
and a parent ion tolerance of 10.0 PPM. Carbamidomethyl
of cysteine was specified as a fixed modification. Variable
modifications were specified including methionine oxidation
and acetylation of peptide n-termini. For protein identification
and quantification, a cut-off value of at least one unique
high confidence peptide per protein, corresponding to a
1% false discovery rate (FDR) at the peptide level and
peptide rank 1 protein was selected. Proteins and peptides
identified and quantified by at least two of three replicates
were used for comparisons. Mass spectrometry data were
obtained at the University of Massachusetts Amherst Mass
Spectrometry Center. Proteome data is deposited in the
EMBL-EBI PRoteomics IDEntifcations Database (PRIDE) under
Accession: PXD021868.
Proteome Data Analysis
Scaffold version 4.9.0, (Proteome Software Inc., USA) was used
to validate peptide and protein calls. Peptide identifications were
accepted at>99.0% probability by the Peptide Prophet algorithm
(28) with Scaffold delta-mass correction. Protein identifications
were accepted at >99.0% probability and containing at least
two identified peptide. Protein probabilities were assigned by
the Protein Prophet algorithm (29). Proteins that contained
similar peptides and could not be differentiated based on
MS/MS analysis alone were grouped to satisfy the principles
of parsimony. In order to generate relative quantification
across samples, result files from Proteome Discoverer were
imported into Scaffold and sf3 files were exported for the
qualitative and quantitative comparisons. Peptide and protein
abundances were normalized based on total sum of peptide and
protein abundances, respectively, and were log10 transformed
prior to the analysis. Multivariate data analysis was carried
out using MetaboAnalyst 4.0 (30) (www.metaboanalyst.ca).
Partial Least Squares Discriminant Analysis (PLS-DA) was
used to maximize the covariance between variables. Variable
importance of projection (VIP) score plot obtained by PLS-
DA identified proteins (VIP score of ≥1.0) responsible for
the clustering of groups. Proteins were annotated with GO
terms using UniProt ID mapping (www.uniprot.org) and KEGG
metabolic pathways were reconstructed using KEGG Mapper.
PLS-DA, VIP, and KEGG metabolic pathways are reported
in Supplementary Figures 1–3. The obtained proteomes were
queried for proteins involved in the hypothetical B. infantis
fucose metabolic pathway based on putative fucose genes
identified in the B. infantis genome.
RNA-seq Transcriptome Library
Preparation
For RNA extraction, cells stored in RNAlater (MilliporeSigma,
Burlington, MA) at −80◦C were centrifuged at 14,000 × g for
3min and cell pellets were washed with 1mL cold 1X PBS
buffer. Total RNA was extracted using Ambion RNAqeous kit
(Life Technologies, USA) according tomanufacturer instructions
with a beadbeating step added to disrupt the cells. Accordingly,
cells were suspended in 600 µL lysis buffer in beadbeating
tubes (100µm Silica Beads; OPS Diagnostics, USA) at 5.5
m/s for 30 sec 1X using a FastPrep 24 bead beader (MP
Biomedicals, USA). RNA concentrations were measured by
a NanoDrop spectrophotometer and samples were subjected
to DNase treatment using the Ambion Turbo DNA-free kit
(Invitrogen, USA) using 2 µL of DNase I for 45min for 25
µL eluted total RNA. The RNA was evaluated for genomic
DNA contamination using qRT-PCR performed on a 7500 Fast
Real-Time PCR System (Applied Biosystems, USA) as described
previously (31). An additional round of DNase treatment was
performed for samples with high levels of residual DNA.
DNase-treated RNA was quantified using the Qubit High
Sensitivity RNA Assay Kit (Life Technologies, USA) and RNA
quality was assessed through RNA integrity number equivalent
(RINe) as determined on a TapeStation 2200 system using High
Sensitivity RNA screen tapes and reagents (Agilent Technologies,
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USA). Samples with RINe >7.0 were subjected to ribosomal
RNA depletion and mRNA purification with the RiboMinus kit
with Magnetic Bead Clean up Module using the custom Pan-
Prokaryote Probe Mix to target bacterial rRNA (Thermo Fisher
Scientific, USA). RNA was quantified using the Qubit High
Sensitivity RNA Assay and rRNA depletion was confirmed on
TapeStation 2200 system. The depleted RNAs (RINe ∼1.0–2.5)
proceeded to sequencing library generation with the NEBNext
Ultra II Directional Library preparation kit (New England
Biolabs, USA). Purification was performed with AmPure XP
beads (Beckman Coulter, USA) and indexed using NEBNext R©
Multiplex Oligos for Illumina Indices (Dual Index Primers Set
1; New England Biolabs Inc., USA) with 8–10 PCR cycles
which varied according to input RNA concentration. The
libraries were quantified using the Qubit double-stranded DNA
(dsDNA) HS assay (Life Technologies, USA). The quality of
library products was measured by high sensitivity DNA screen
tapes on the TapeStation 2200 system. Sequencing libraries
were pooled in equimolar concentrations (4 nM) and denatured
immediately prior to sequencing following Illumina pooled
library instructions. Sequencing was performed on an Illumina
NextSeq platform (NextSeq 500/550 High Output Kit v2.5,
paired-end, 150 cycles, 5% Phi-X) at the Genomics Resource
Laboratory, University of Massachusetts Amherst. Raw reads
are publicly deposited in the NCBI Gene Expression Omnibus
database (https://www.ncbi.nlm.nih.gov/geo/) under accession
number GSE159189.
Transcriptome Informatic and Statistical
Analysis
Raw reads were uploaded to the Massachusetts Green
High-Performance Computing Cluster used for all
computational/statistical analyses unless specifically noted.
Sequencing adaptors were trimmed during de-multiplexing.
The reads were aligned to the reference Bifidobacterium longum
subsp. infantis ATCC 15697 (NCBI accession number: NC
011593.1) using bowtie-2 (v2.3.4.3) (32). Total and non-unique
gene reads aligning to a specific genomic locus, as well as
calculated raw counts (HTSeq count, v0.10.0) (33) were obtained
for differential expression analysis.
Differential Gene Expression
In order to identify and quantify the magnitude of differentially
expressed genes, the R package DESeq2 was used to analyze
the raw count data (34). Genes with a sum count <50 were
removed from analysis by pre-filtering. DESeq2 applies the Wald
test for statistical analysis with adjusted p ≤ 0.05 designated as
statistically significant. Principal component analysis (PCA) was
performed and plots were visualized using DESeq2 (34). Gene
maps were created and visualized using the R package genoplotR
following B. infantis ATCC 15697 reference genome obtained
from NCBI (NC_011593.1) and colored with corresponding z–
score (35, 36). Z–score for each gene of interest was calculated
using the following equation:
z− score =
Expression−Mean expression across all samples
Standard deviation
where expression corresponds to the normalized counts of the
gene of interest. Z-scores were visualized using a heatmap or
gene map. Volcano plots were created and visualized using the
R package EnhancedVolcano (37). Predicted gene functions were
determined using a combination of BLAST (38) and KEGG
(http://www.genome.jp/kegg~searches).
Statistical Analyses
Statistical analysis of growth kinetics was performed using
the final OD600 as a measure of total biomass. Final OD600
was subjected to one-way analysis of variance and Tukey’s
HSD for multiple comparisons between carbohydrate source.
Metabolite concentrations were subjected to one-way analysis
of variance and Tukey’s HSD test for multiple comparisons
between carbohydrate source. Fold change in gene expression
was subjected to the Wald test during processing in DESeq2
(34). Z-scores generated from normalized counts were subjected
to one-way analysis of variance and Tukey’s HSD test
for multiple comparisons between 2′FL concentrations and
carbohydrate source.
Experimental Layout
Co-fermentation of free fucose with glucose and lactose in both
large volume (5mL) and standard 96-well microplate formats
was performed. Large volume cultures were used to obtain
sufficient biomass to perform intra- and extracellular metabolite
assays as a function of growth time during co-fermentation
of free fucose and glucose as well as during growth on 2′FL
as a sole carbohydrate. Proteomic and transcriptomic analyses
were performed using large volume cultures in order to obtain
sufficient biomass to extract the necessary quantities of protein
and RNA. 96-well microplate growth assays were performed in
all other cases where growth kinetics and metabolite production
were examined. A brief schematic of the experimental layout is
included in Supplementary Figure 4.
RESULTS AND DISCUSSION
B. infantis Utilizes Free Fucose as a
Carbohydrate Source
In order to understand B. infantis metabolism of free fucose
and HMO-derived fucose, B. infantis ATCC 15697 was subjected
to growth on fucose as a sole carbohydrate source and in co-
fermentation with other sugars. Co-fermentation was performed
due to prior observation of inconsistent B. infantis growth on
fucose as the sole carbohydrate source which increased with the
addition of trace glucose (14, 20, 21). Growth was performed
in a standard 96-well plate format to maximize sensitivity
and throughput and percentage carbohydrate substrate added
are reported as wt/vol. Consistent with Bunesova et al. (14)
supplementing free fucose with a trace amount of glucose (0.1–
0.2%) resulted in higher final biomass (Figures 1A,B). B. infantis
ATCC 15697 growth on free fucose as a sole carbohydrate source
was reproducible and consistent across biological replicates.
Co-fermentation of 0.1% glucose and 1.9% fucose resulted in
significantly greater growth (final OD600 = 0.38 ± 0.09) relative
to 0.1% glucose alone (final OD600 = 0.22 ± 0.08, p = 9.9E-5)
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FIGURE 1 | Growth curves of ATCC 15697 in (A) co-fermentation of 1.9% fucose and 0.1% glucose, (B) co-fermentation of 1.8% fucose and 0.2% glucose and on a
corresponding concentration of glucose as a sole carbohydrate source shows distinct changes in growth rate during co-fermentation. The region where growth
kinetics deviate and are best fit with a second growth rate is noted by the bold circle. Growth curves of ATCC 15697 on (C) co-fermentation of 1.9% fucose and 0.1%
glucose and on individual carbohydrate sources. Samples were analyzed for metabolite concentrations at each data point. Concentrations of fucose and
1,2-propanediol (D) during co-fermentation of 1.9% fucose and 0.1% glucose are inversely related and in stoichiometric agreement with the proposed fucose
metabolic pathway. Error bars denote standard error of the mean.
(Figure 1A). Moreover, growth on 1.8% fucose and 0.2% glucose
(final OD600 = 0.50 ± 0.06) is also significantly higher than
growth on 0.2% glucose alone (final OD600 = 0.44 ± 0.002, p =
0.02) (Figure 1B). Growth on 1.8% fucose and 0.2% glucose is
also significantly higher than growth on 1.9% fucose and 0.1%
glucose (p = 0.003). Growth on 0.2% glucose is significantly
higher than growth on 0.1% glucose (p= 2.04E-8).
Growth in co-fermentation at both concentrations of fucose
and glucose exhibits two distinct regions with different growth
rates. In both conditions, the growth rate in the first regime
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(k = 0.43, k = 0.57) is in concordance with the growth rate
observed in fermentation of glucose as a sole carbohydrate
source (k = 0.42, k = 0.54). Given the shift in growth rate
and the relative length of each region, it is possible that the
cells are transitioning from glucose to fucose metabolism as the
limiting concentration of glucose is exhausted. Depletion of the
preferred carbohydrate source is the most common driver of
diauxic shifts in microbial systems. Interestingly, the growth rate
increases across this diauxic transition during co-fermentation
of 1.9% fucose and 0.1% glucose (k = 0.43–0.58) and decreases
during co-fermentation of 1.8% fucose and 0.2% glucose (k =
0.57–0.43). Thus, it is possible that the initial concentration of
glucose influences the direction of growth rate change. Biomass
accumulation on 0.1% glucose is severely restricted indicating
that B. infantis ATCC 15697 does not have sufficient substrate
at this concentration. Therefore, it is concluded that increased
growth in co-fermentation is due to the inclusion of fucose as a
fermentable carbohydrate.
In order to assess metabolite production as a function
of growth, larger volume co-fermentation was performed to
identify intracellular metabolites from sufficient biomass. Higher
volume co-fermentation of glucose and fucose (Figure 1C)
was consistent with the smaller volume 96-well format
(Figures 1A,B), although exhibited lower OD600 values overall.
Again, growth in co-fermentation of 0.1% glucose and 1.9%
fucose was significantly increased relative to 0.1% glucose (p
= 0.004) and 1.9% fucose (p = 0.02) as a sole carbohydrate
source. In the large volume format, B. infantis ATCC 15697
does not significantly utilize free fucose as a sole carbohydrate
source relative to the negative control (i.e., no added sugar) (p
= 0.1) (Figure 1C). These results are consistent with previous
observations that several B. infantis strains do not grow efficiently
on fucose and only grow in the presence of trace glucose (14).
In contrast, co-fermentation of 0.1% lactose and 1.9% fucose
is driven predominately by lactose metabolism as suggested by
insignificant difference to final OD600 relative to growth on
0.1% lactose alone (Supplementary Figure 5, p = 0.07). This is
not surprising given the efficient metabolism of lactose by B.
infantis ATCC 15697 which likely prioritizes lactose over fucose.
The presence of a second growth phase in co-fermentation
of lactose and fucose (Supplementary Figure 5) suggests that
fucose is being metabolized, similar to co-fermentation of the
same concentrations of glucose and fucose (Figure 1A). Fucose
metabolism during co-fermentation with lactose is supported
by 1,2-PD production and disappearance of fucose from the
medium (Figure 1D, Supplementary Table 1).
1,2-Propanediol Is Produced in
Stoichiometric Accordance With Free
Fucose Utilization
Given that B. infantis ATCC 15697 co-ferments limiting
concentrations of glucose or lactose and excess fucose, as
well as free fucose, fermentative intermediates were profiled to
clarify the fucose utilization pathway. A mechanistic pathway
(Supplementary Figure 6) was proposed by Bunesova et al (14)
and supported by James et al in Bifidobacterium kashiwanohense
and Bifidobacterium breve (11). This hypothetical pathway
reflects rhamnose metabolism in Campylobacter sp. and X.
campestris and features several intermediate metabolites to be
potentially assayed (11, 14). L-fucono-1,4-lactone was selected
as a metabolite marker to track due to its stability, exclusivity
to the putative fucose pathway, and it yields a single spectral
peak. Conversely, L-fuconate exhibits several peaks that are
interspersed among the linear form of fucose. As such,
intracellular metabolites were measured during co-fermentation
of 0.2% glucose and 1.8% fucose. The higher concentration of
glucose was used in order to achieve sufficient biomass to reliably
detect L-fucono-1,4-lactone that is expected to be present in low
concentrations. The presence of a lactate, pyruvate, and 1,2-PD
signal confirmed that sufficient biomass was generated to detect
intracellular metabolites (data not shown).
Despite the predicted stability of L-fucono-1,4-lactone, the
metabolite was not detected at any point during growth
on 0.2% glucose and 1.8% fucose (Supplementary Figure 7).
There is, however, evidence of intracellular 1,2-PD as it was
observed in the GC-MS chromatogram as a shallow, broad peak
appearing very close to the solvent (data not shown). If fucose
is metabolized through a L-fucono-1,4-lactone intermediate it
may be highly transient or present in concentrations below the
limit of detection. Although intracellular L-fucono-1,4-lactone
was not detected, the presence of intracellular 1,2-PD indicates
that fucose metabolism proceeds during biomass accumulation.
Given that 1,2-PD is a secreted metabolic end product and
expected to be found in higher concentrations in the extracellular
matrix relative to intracellular levels, extracellular 1,2-PD served
as a marker for fucose metabolism. Accordingly, we hypothesized
that B. infantis ATCC 15697 secretes extracellular 1,2-PD
corresponding with a decrease in fucose as a hallmark of fucose
metabolism (Figure 1D).
Unlike glucose or galactose, fucose is not predicted to enter
the bifidobacterial central metabolic pathway, termed the bifid
shunt. This assumption is based on fucose metabolism in
other bacterial systems and on the unique characteristics of
the bifid shunt. Instead, it is hypothesized that an equimolar
ratio of pyruvate and 1,2-PD is produced per mole of fucose
consumed. Thus, 1,2-PD would be produced at the same
rate that fucose is expended. Pyruvate would be catabolized
and secreted as lactate, formate, and/or acetate to recycle
cofactors. Extracellular metabolites produced during growth
on fucose are provided in Table 1. 1,2-PD is produced at 0.5
times fucose consumption during co-fermentation of fucose
and glucose. During growth on fucose as a sole carbohydrate
source, 1,2-PD is produced at 0.44 times the consumption
of fucose. While these ratios are not the expected equimolar
production, it is important to note that the uncertainty in fucose
concentration is large. Accounting for uncertainty in fucose
concentration provides a range of the ratio of 1,2-PD production
to fucose disappearance of 0.3–1.4 during co-fermentation of
fucose and glucose and 0.3–0.7 during growth on free fucose.
Furthermore, some deviation from the theoretical ratio of 1 is
anticipated due to variation in growth state. Overall, B. infantis
ATCC 15697 is observed to produce 1,2-PD as a result of
fucose metabolism.
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TABLE 1 | B. infantis extracellular metabolite production during growth in co-fermentation of fucose and glucose and on fucose and glucose as sole carbohydrate
sources.
Glucose (mM) Fucose (mM) Lactate (mM) Formate (mM) Acetate (mM) 1,2-PD (mM) Ace:Lac Form:Ace
1.9% fucose/0.1% glucose −5 ± 1 −26 ± 16 +1.6 ± 0.6 +11.8 ± 0.6 +15.0 ± 0.1 +13 ± 1 3.08 0.70
1.9% fucose ND −20 ± 7 +0.3 ± 0.8 +6.7 ± 0.9 +8.0 ± 0.7 +8.8 ± 0.2 2.26 1.02
0.1% glucose −0.96 ± 0.09 ND +0.10 ± 0.07 +0.1 ± 0.1 +0.58 ± 0.1 ND 0.71 0.99
Change in concentration is calculated using extracellular concentrations prior to growth and following stationary phase. ND, not detected.
TABLE 2 | B. infantis extracellular metabolite production during growth on 2′fucosyllactose is similar to that both in co-fermentation of fucose and lactose and on fucose
and lactose as sole carbohydrates.
Carbohydrate Lactate (mM) Acetate (mM) Formate (mM) 1,2-PD (mM) 1[Fucose] (mM) Ace:Lac Form:Ace
Raw Norm Raw Norm Raw Norm Raw Norm
0.8% 2′FL 16 ± 1 16 ± 1 40.0 ± 0.8 40.0 ± 0.8 11.9 ± 0.5 11.9 ± 0.5 7.6 ± 0.1 7.6 ± 0.1 −7.5 ± 0.4 2.5 0.3
0.8% fucose 3.14 ± 0.08 18.97 ± 0.08 3.5 ± 0.2 21.3 ± 0.2 2.6 ± 0.5 15.6 ± 0.5 5.30 ± 0.08 21.01 ± 0.08 −5.3 ± 0.9 1.1 0.7
0.8% lactose 30.2 ± 0.5 22.9 ± 0.5 56 ± 1 42 ± 1 3.6 ± 0.2 2.7 ± 0.2 ND ND ND 1.8 0.06
0.8% fucose/0.8%
lactose
28.1 ± 0.3 22.4 ± 0.3 45.5 ± 0.7 36.3 ± 0.7 3.9 ± 0.3 3.1 ± 0.3 4.07 ± 0.05 3.25 ± 0.05 −4.8 ± 0.4 1.6 0.09
Change in concentration is calculated using extracellular concentrations prior to growth and following stationary phase. ND, not detected.
The acetate:lactate ratio during co-fermentation of glucose
and fucose surpasses the theoretical ratio of 1.5 secreted
during hexose metabolism (Table 1). As compared to efficiently
fermented carbohydrates such as lactose (Table 2), lactate
concentrations greatly decreased and formate concentration
increased during growth on fucose. This metabolic shift to
favor formate secretion may be to prioritize ATP production
through a branch in the bifid shunt. Similar observations have
been reported for B. infantis ATCC 15697 (39) and other
Bifidobacterium species (40) during inefficient metabolism of
neutral HMOs. An acetate:lactate ratio of 0.99 during growth on
0.1% glucose may be due to poor growth on such a limiting sugar
concentration, and thus deviates from the theoretical ratio of 1.5.
Increased formate:acetate ratios are consistent with a shift
in pyruvate metabolism. When more than 50% acetyl-CoA is
converted to acetate by B. longum, the theoretical formate:acetate
ratio is approximately 0.4 (41). Here, B. infantis ATCC 15697
has surpassed that threshold, suggesting that there is a shift
to produce more acetyl-CoA than lactate from pyruvate. The
increased ratios are expected with the inefficient fermentation of
fucose as a sole carbohydrate source. These results support the
hypothesis that B. infantis ATCC 15697 utilizes free fucose as a
carbohydrate to support growth, although fucose fermentation is
somewhat inefficient under these experimental conditions.
1,2-Propanediol Is Produced in
Stoichiometric Accordance With 2′FL
Utilization
Similar to fucose metabolism, 2′FL is metabolized by B.
infantis ATCC 15697 to produce 1,2-PD (Figures 2A–C) when
fermenting substrates at slightly higher concentrations than
those found in human milk (42). Each molecule of 2′FL is
composed of a lactosyl and fucosyl moiety, thus utilization of
2′FL approximates fucose utilization. As with co-fermentation
of fucose and glucose, 1,2-PD production would be expected
to be equivalent to fucose. In three tested conditions (0.8%
2′FL, 0.8% fucose, and 0.8% fucose/0.8% lactose) the decrease in
fucose or 2′FL concentration is nearly identical to the production
of 1,2-PD (Table 2). In both instances formate production is
increased fivefold (5.8-fold for free fucose and 4.4-fold for 2′FL)
in a comparison of free fucose and 2′FL metabolism (Table 2).
Moreover, lactate production is decreased relative to growth on
lactose when normalized to final OD600. In contrast, acetate
production is reduced while subsisting on fucose which could
be an artifact of poor growth or otherwise confounded due to
metabolism of the lactosyl component of 2′FL. A co-fermentation
of 0.8% fucose and 0.8% lactose was used to functionally
approximate fermentation of integrated 0.8% 2′FL as a sole
carbohydrate source (Table 2). Whereas, absolute metabolite
concentrations of the fucose/lactose co-fermentation are in closer
agreement with those during growth on 2′FL, the formate and
1,2-PD concentrations during fucose metabolism are reduced
with the addition of the more efficiently utilized lactose. As
such, it is difficult to derive conclusions regarding free fucose
metabolism in direct comparison to 2′FL-derived fucose.
Limiting Concentrations of Mono- and
Disaccharide Residues of 2′FL Increase
Fucose Metabolism
In order to clarify the boundaries of fucose metabolism in
the presence of a preferred sugar, B. infantis was grown in
co-fermentation of excess fucose and limiting concentrations
of lactose, glucose, and galactose. Initial co-fermentation of
limiting lactose (0.1%) (Supplementary Figure 5) resulted in
variable growth indicating that this concentration is too low to
consistently support growth. Thus, co-fermentation of 2% fucose
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FIGURE 2 | Growth curves of ATCC 15697 growth in (A) co-fermentation of excess fucose and limiting lactose as compared to 2′fucosyllactose. Co-fermentation of
fucose and limiting lactose shows similar behavior to fermentation of 2′fucosyllactose and results in increased growth over individual carbohydrate sources.
Co-fermentation of (B) excess fucose and limiting concentrations of mono- and di-saccharide components of 2′fucosyllactose shows a consistent synergistic effect.
1,2-Propanediol production (C) during co-fermentation is equal to or higher than 2′fucosyllactose and higher than growth on fucose as a sole carbohydrate source.
Error bars denote standard error of the mean.
and slightly higher concentrations (0.2%) of glucose, galactose,
and lactose were used (Figure 2B). Co-fermentation of fucose,
glucose, and galactose produced the highest biomass as measured
by final OD600 (Figure 2B). Co-fermentation of fucose with
glucose or lactose produced roughly equivalent final OD600 as
fermentation of 2′FL as the sole carbon source. In contrast, co-
fermentation of fucose and galactose produced a lower final
OD600. Regardless of the co-fermented substrate, growth in co-
fermentation with fucose achieved higher biomass than growth
on fucose or the limiting carbohydrate alone. Furthermore,
the final OD600 achieved in co-fermentation was higher than
the sum of final OD600 achieved during growth on individual
components as sole carbohydrate sources (lactose shown in
Figure 2A, additional sugars not shown).
In accordance with increased growth, final 1,2-PD
concentrations increased during growth in co-fermentation
relative to growth on 2% fucose as a sole carbohydrate
source (Figure 2C). All co-fermentations exhibit significantly
higher 1,2-PD secretion relative to growth on fucose alone
[fucose/glucose (p = 6.76E-8), fucose/galactose (p = 0.02),
fucose/lactose (p = 1.24E-4), fucose/glucose/galactose (p
= 1.79E-8)]. Moreover, 1,2-PD production was unchanged
(galactose or lactose) or increased [glucose (p = 0.003),
glucose/galactose (p = 1.65E-7)] during co-fermentation as
compared to 1,2-PD production during growth on 0.8% 2′FL.
Fucose metabolism and central carbohydrate metabolism are
linked as evident from increased final OD600 corresponding to
increased 1,2-PD concentration.
Clearly fucose is not a preferred carbohydrate source for
B. infantis ATCC 15697 and is not efficiently metabolized
as a sole carbohydrate source regardless of the addition of
limiting co-fermented sugars. Despite this inefficientmetabolism,
co-fermentation significantly increases growth and hallmarks
of fucose metabolism. This phenomenon was also observed by
Bunesova et al in that bifidobacterial growth on free fucose
as a sole carbohydrate source was greatly improved by the
inclusion of trace (0.4mM) glucose (14). It is possible that a
metabolite represses the fucose pathway as a result of fucose
catabolism or carbon flux through the bifid shunt. James et al.
putatively linked a LacI-family regulator in B. kashowanihense
(fumR) to fucose metabolism, although mechanistic details
of regulatory interactions remain unresolved (11). B. infantis
ATCC 15697 possesses a homolog of fumR (Blon_RS01775) and
this putative repressor may restrict fucose metabolism in the
presence of sufficient concentrations of efficiently utilized sugars
(e.g. glucose, galactose, and lactose). It is possible that fucose
transport is repressed in the presence of high concentrations
of efficient substrates, similar to the preferential metabolism
of lactose over glucose observed in B. longum (43). In this
experimental system, fucose transport is likely not hindered by
excess lactose, as extracellular fucose concentrations diminish
uniformly regardless of growth solely on fucose or in co-
fermentation with lactose (Table 2). The variability within LacI-
family allosteric activities suggest that bifid shunt and/or fucose-
derived metabolites potentially regulate fucose metabolism (44).
Furthermore, fucose metabolism is not repressed by limiting
co-fermented carbohydrates. This is evidenced by similar
concentrations of secreted 1,2-PD on excess 2′FL and excess
fucose co-fermented with limiting sugars.
Utilization of Higher Concentrations of 2′FL
Does Not Promote Efficient B. infantis
Growth
2′FL concentrations in human milk vary between and within
populations depending on multiple factors including maternal
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FIGURE 3 | Growth curves of ATCC 15697 growth on (A) 2′fucosyllactose as a sole carbohydrate source is highly concentration-dependent. Metabolite production
(B) appears to be consistently dependent on 2′fucosyllactose concentration, but concentration dependence does not persist when (C) metabolite concentrations are
normalized to account for differences in biomass. Error bars denote standard error of the mean.
TABLE 3 | B. infantis 2′fucosyllactose consumption and 1,2-propandiol production during growth on 2′fucosyllactose as a sole carbohydrate source is not
concentration-dependent when differences in final biomass are accounted for. However, acetate:lactate and formate:acetate ratios show some subtle variation with
2′fucosyllactose concentration.
2′FL conc. (%w/v) 2% 1.8% 1.5% 1% 0.8% 0.6% 0.4% 0.2%
Final OD600 (± stdev 0.63 ± 0.04 0.79 ± 0.02 0.89 ± 0.01 0.99 ± 0.02 1.13 ± 0.01 1.17 ± 0.06 1.10 ± 0.02 0.39 ± 0.03
Acetate:Lactate 3.2 3.2 3.3 3.3 2.9 2.9 2.4 2.0
Formate:Acetate 0.34 0.34 0.37 0.37 0.34 0.29 0.31 0.24
1[2′FL] (mM) −7 ± 2 −5 ± 2 −2 ± 1 −6 ± 2 −7 ± 1 −8 ± 2 −11.1 ± 0.3 −7 ± 2
1[1,2–PD] (mM) +7.57 ± 0.07 +7.7 ± 0.1 +8.2 ± 0.2 +7.29 ± 0.05 +8.4 ± 0.4 +8.7 ± 0.4 +7.5 ± 0.1 +3.4 ± 0.2
Normalized 1[2′FL] (mM) −14 ± 2 −7 ± 2 −2 ± 1 −6 ± 2 −6 ± 1 −7 ± 2 −10.1 ± 0.3 −17 ± 2
Normalized 1[1,2-PD] (mM) +12.02 ± 0.07 +9.8 ± 0.1 +9.2 ± 0.2 +7.36 ± 0.05 +7.4 ± 0.4 +7.5 ± 0.4 +6.8 ± 0.1 +8.8 ± 0.2
Change in extracellular concentration is calculated using concentrations prior to growth and following stationary phase. ND, not detected.
secretor status (6, 7, 42, 45–47). In order to test the hypothesis
that the fucose utilization phenotype responds to 2′FL in a
concentration-dependent manner, B. infantis ATCC 15697 was
grown on 2′FL as the sole carbohydrate source at concentrations
ranging from 0.2% (i.e., limiting) to 2% (i.e., exceeds human milk
concentrations). Thus, concentration-dependent growth on 2′FL
would result in higher final OD600 and higher 1,2-propanediol
production. Interestingly, and counter to this hypothesis, 2% 2′FL
promotes moderate B. infantis ATCC 15697 growth, reaching
an OD600 of 0.64 ± 0.06. Accumulated biomass increases
with diminishing 2′FL concentrations (Figure 3A) until 2′FL is
limiting to exhibit an inverse relationship. A more pronounced
diauxic curve is exhibited as 2′FL concentration falls below 1%
and is suppressed again at concentrations below 0.6%. It is
currently unclear how this concentration-dependence relates to
fucose metabolism.
Absolute concentrations of secreted metabolites follow the
parabolic trend observed in final OD600 (Figure 3B); however,
this trend does not hold when metabolite concentrations are
normalized to final OD600 to account for biomass variation
(Figure 3C). As a result, the discordance between cellular
growth and metabolite production is apparent and indicates
a significant biological phenomenon. When normalized to
biomass, formate is secreted in a consistently positive slope
with increasing 2′FL. Acetate production also exhibits a net
positive slope except at the lowest 2′FL concentration, which
is severely limiting. The increase in formate and acetate
production suggest that metabolic flux increases along with
2′FL concentrations. Formate production is small relative
to the increase in acetate concentrations coinciding with
increasing 2′FL concentration and, thus, does not significantly
change the formate:acetate ratio (Table 3). Whereas normalized
formate and acetate production are concentration-dependent,
normalized lactate production does not exbibit a consistent
relationship with 2′FL concentration. The relatively constant
lactate concentration is consistent with increased formate and
acetate production given that these metabolites are often
increased at the expense of lactate production (41, 48–51).
The specific metabolic end products that were quantified
were not significantly impacted by 2′FL concentration despite
significant changes in biomass accumulation with changing
2′FL concentration.
A potential factor in inhibition of growth with increasing
2′FL concentration is a potential toxicity of 1,2-PD, as 1,2-PD
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FIGURE 4 | Proposed fucose pathways based on proteome during growth on (A) free fucose and (B) 2% 2′fucosyllactose as sole carbohydrate sources. Gene
symbols are given in light blue above the reaction arrows and corresponding protein names below.
concentration increases with that of 2′FL (Figure 3B). To
test this, a growth inhibition assay indicated that 1,2-PD is
only slightly inhibitory between 168 and 0.08mM with a
difference in OD600 of 0.107 ± 0.007 (p = 9.5E-8) between the
highest and lowest 1,2-PD concentrations. Similarly, the growth
inhibition assay of lactate (i.e., inhibitory at high concentrations)
Frontiers in Nutrition | www.frontiersin.org 11 November 2020 | Volume 7 | Article 583397
Dedon et al. Bifidobacterium infantis Fucose Metabolism
indicates a similar slight inhibition between 144 and 0.07mM
lactate (1OD600 of 0.150 ± 0.005, p = 3.0E-7). Neither
metabolite accumulates to inhibitory concentrations prior or
during growth. 1,2-PD reaches a maximum concentration of 8.6
± 0.4mM at 0.6% 2′FL. Therefore, it is unlikely that secreted
1,2-PD or other quantified end-product metabolites impact
growth at higher concentrations of 2′FL. It is possible that
fucose metabolism is repressed by some unknown mechanism.
Thus, proteomics and transcriptomics were conducted to
examine global regulatory networks during fucose metabolism to
better understand the relationship between fucose, lactose, and
2′FL utilization.
The Proteome Contains Hallmarks of
Putative Bifidobacterial Fucose Metabolic
Pathway
The B. infantis proteome was interrogated for signals of pathways
active during fucose catabolism. The proteome during growth
on free fucose as a sole carbohydrate exhibits features consistent
with the pathway proposed for B. kashowanohense, albeit yet to
be validated incisively (Figure 4A) (11, 14) Figure 4 integrates
proteins within the proteome encoded by the genes of interest in
the hypothetical B. infantis fucose metabolic pathway. Putative
fucose metabolism proteins were observed in at least two of
three biological replicates. Transport-associated proteins were
identified in relatively low abundance, which may be due to their
spanning the cell membrane and, thus, tendency to collapse in
the insoluble proteome fraction. Nevertheless, transport proteins
were observed in two of three biological replicates.
An ABC transporter linked to 2′FL (Blon_RS01780-
RS01790) (4) is expressed during growth on fucose as a sole
carbohydrate. This indicates that fucose signals 2′FL metabolism
to initiate and reflects likely overlapping processes to catabolize
free or integrated fucose. Partial evidence of a secondary
transporter (Blon_RS11370-RS11380) was identified in the
proteome. Proteins corresponding to Blon_RS11370 (FumS) and
Blon_RS11380 (FumT2) were detected in two of three replicates,
and Blon_RS11375 (FumT1) was not observed.
The fucose proteome is in agreement with 1,2-PD production
(Table 1). Although intracellular L-fucono-1,4-lactone was
not detected via GC-MS, proteins with KEGG orthologs
corresponding to L-fucono-1,4-lactone and L-fuconate synthesis
were present in the proteome. These proteins with putative fucose
metabolic functions include L-fucose dehydrogenase (FumC),
L-fuconolactone hydrolase (FumD), as well as L-fuconate
dehydratase (FumE). Furthermore, differential expression of
L-fuconolactone and L-fuconate-related proteins was observed
during growth on free fucose as compared to growth on lactose.
FumD (Blon_RS11950) showed a log2 fold change of 13.1 (p
= 5.95E-7) and two orthologs of FumE (Blon_RS11965 and
Blon_RS12115) showed log2 fold changes of 15.4 (p = 1.39E-5)
and 1.7 (p = 0.02). If these enzymes function as predicted,
L-fucono-1,4-lactone and L-fuconate may be produced as highly
transient intermediates during fucose metabolism.
2′FL Induces a Proteomic Signature That
Reflects a Shared Metabolic Pathway With
Free Fucose
The comparison between the proteomes of two 2′FL
concentrations of free fucose indicate close similarity between
growth conditions (Figure 4B). Differential expression of FumD
(Blon_RS11950) (log2 fold change 12.1, p = 0.004) and FumE
(Blon_RS11965) (log2 fold change 14.0, p = 9.75E-6) are also
observed during growth on 2% 2′FL as compared to lactose.
Unlike the free fucose proteome, L-fucose permease (FucP) was
not detected during growth on 2′FL. Thus, it is likely that there
is a single metabolic pathway for fucose catabolism once fucose
is translocated across the cell envelope by B. infantis ATCC
15697. This is based on expression of the same fucose-associated
proteins regardless of conditions and variation in the specific
transport proteins detected. During growth on 2% 2′FL, two
orthologs of FumS (Blon_RS01790 and Blon_RS11370) show
significantly increased expression relative to lactose (log2 fold
change 12.6, p = 0.0004; 9.3, p = 0.005, respectively). FumS
was not seen to be significantly differentially expressed during
growth on fucose as compared to lactose. Interestingly, fucose
may induce the cell to translocate 2′FL via dedicated ABC
transporters, whereas 2′FL may not provide the converse signal
to transport fucose through FucP.
Varying 2′FL Concentration Does Not
Significantly Alter the B. infantis Proteome
2′FL concentration impacts the B. infantis growth phenotype
(Figure 3A) which is not fully reflected in normalized metabolite
concentrations (Figures 3B,C). Using the proposed pathway in
B. kashowanohense as a reference (11), two 2′FL concentrations
yielded highly similar proteomes at 2% and 0.8% 2′FL as
depicted in Figure 4B and Supplementary Figure 8, respectively.
FumT2 provides a minor exception in that the 2′FL-associated
transport permease was identified with high confidence in all
2% 2′FL replicates, and 2 of 3 at 0.8% 2′FL. It is likely that
this is not biological variation, rather due to low abundance
of the protein. Fucose metabolism-related proteins are not
significantly differentially expressed during growth on 0.8% 2′FL
as compared to growth on 2% 2′FL during mid-log phase. It
cannot be excluded that varying 2′FL concentrations impact
relative levels of expressed protein at later stages in growth, when
the divergence of growth phenotypes is more pronounced.
2′FL Induces Fucose-Associated Gene
Expression in the B. infantis Transcriptome
Regardless of 2′FL concentration (0.8 and 2%) the B. infantis
ATCC 15697 transcriptomes are highly similar, as observed
for their cognate proteomes. This is evidenced by low sample-
to-sample distance between the two 2′FL concentrations and
over two-fold higher sample-to-sample distance between 2′FL
and lactose fermentations (Figure 5A) as well as clustering in
the PCA plot (Supplementary Figure 9). Volcano plots confirm
this observation as well (Figures 5B,C). There are relatively
few genes differentially expressed between 2′FL concentrations
(Figure 5D). Despite efforts to scale-up, the inefficient growth
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FIGURE 5 | B. infantis gene expression is similar during growth on 0.8% and 2% 2′fucosyllactose as compared to during growth on lactose as seen from (A)
sample-to-sample distance. While gene regulation is similar, there are several genes that show concentration-dependent regulation when volcano plots are used to
compare (B) 0.8% 2′fucosyllactose and lactose, (C) 2% 2′fucosyllactose and lactose, and (D) 0.8% and 2% 2′fucosyllactose.
FIGURE 6 | Gene maps show that there is differential regulation across the entire fucose metabolic pathway during growth on (A) 0.8% 2′fucosyllactose, (B) 2%
2′fucosyllactose, and (C) lactose as described by z-scores calculated from normalized count data. Gene annotations and predicted functions are provided in
Supplementary Table 2.
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on free fucose did not generate sufficient quality and quantity of
RNA for transcriptomics.
Interestingly, 2′FL induces differential expression of the
majority of proposed fucose metabolism genes relative to
lactose (p≤ 0.01; Figure 6, Supplementary Figures 10, 11). The
exceptions are fuconate dehydratase (Blon_RS01795), fucose
permease (Blon_RS11955), and solute-binding protein fumS
(Blon_RS12150) which did not exhibit significant differences.
These genes may not be expressed, or they may have similar
constitutive expression levels between conditions. In addition,
these three genes have multiple copies within the ATCC
15697 genome. Additional fumE paralogs are differentially
expressed, with Blon_RS11965 highly upregulated (log2
fold change >4) whereas Blon_RS12115 is downregulated
(log2 fold change<-1.5). Blon_RS01810 encodes another
putative fucose permease which is downregulated (log2 fold
change<-0.65, p≤0.001). Blon_RS01790 (log2 fold change>3),
Blon_RS11370 (log2 fold change>1.3), and Blon_RS12135
(log2 fold change < −1.4) encode fumS-like genes and are
differentially regulated. There are several potential explanations
for these observations, and they likely all contribute uncertainty.
Foremost is that the putative B. kashowanohense pathway
is incompletely characterized and validated including the
constituent genes and their activities. Moreover, B. infantis
fucose metabolism may diverge from B. kashowanohense, and
paralogs may have multiple functions potentially unrelated to
fucose metabolism.
Despite differential regulation between 2′FL relative to
lactose, the transcriptomes remain relatively static regardless
of 2′FL concentration (Figure 6). Two putative fumS genes
(Blon_RS01790, p = 0.004 and Blon_RS12150, p = 0.002)
and a fumT1 gene (Blon_RS01785, p = 0.01) are down-
regulated on 2% 2′FL relative to 0.8% 2′FL (Figure 6).
This down-regulation may reflect the lower growth observed
on higher concentrations of 2′FL. In addition, 2% 2′FL
down-regulates a fucose dehydrogenase (Blon_RS11960; p <
0.01) and fuconate dehydratase (Blon_RS11965; p < 0.05).
This down-regulation is consistent with lower growth on 2′FL.
Similarly, a putative lactaldehyde reductase (Blon_RS02730; p
< 0.0001) was downregulated during growth on 2% relative
to 0.8% 2′FL. This enzyme could catalyze the conversion of
lactaldehyde to 1,2-PD. Thus, differential regulation of fucose-
related genes may reflect the non-linear relationship between
2′FL concentration and growth phenotype.
Differential regulation is not limited to the fucose-related
genes previously identified. Given that the changes in metabolite
production are not specific to fucose utilization (i.e., acetate,
lactate, and formate) between 2′FL and lactose (Table 2),
differential expression in the central pathway was examined.
The majority of genes involved in the central pathway
are up-regulated during growth on 2′FL as compared to
lactose (Supplementary Figure 12). ROK family glucokinase
Blon_RS02865 (p < 0.0001) and acetaldehyde-CoA/alcohol
dehydrogenase Blon_RS11570 (p < 0.001) are both down-
regulated during growth on 2′FL as compared to growth on
lactose at both concentrations of 2′FL. Reduced glucokinase
and acetaldehyde-CoA/alcohol dehydrogenase expression was
also observed in B. kashiwanohense APCKJ1 during growth on
2′FL as compared to growth on both sorbitol and lactose (11).
Genes implicated in sialic acid metabolism are similarly down-
regulated in a consistent manner between both concentrations
of 2′FL as compared to lactose (Supplementary Figure 13).
This suggests that metabolism of the neutral fucosylated 2’FL
regulates acidic HMO metabolism. It is unclear if this is a
feature of all fucosylated HMOs or unique to the abundant 2’FL
oligosaccharide species.
CONCLUSIONS
B. infantis ATCC 15697 metabolizes both free and HMO-derived
fucose through a common and likely phosphorylation-
independent pathway to produce 1,2-PD. During fucose
metabolism, carbon is shunted from lactate and toward
formate and 1,2-PD production. This metabolic shift differs
somewhat during free fucose metabolism relative to that of 2′FL.
Although the inefficient metabolism of free fucose hinders direct
comparisons in this respect. The shift to prioritize formate and
1,2-PD production may impact trophic relationships within
the infant gut microbiome. Accordingly, it has been reported
that the infant-associated Eubacterium hallii metabolizes 1,2-
PD to produce short chain fatty acids butyrate, formate, and
propionate. All of which potentially benefit the gut microbiome
and overall infant development (52, 53). When presented
with equal concentrations of fucose and lactose, B. infantis
ATCC 15697 preferentially metabolizes the preferred lactose
with minimal fucose utilization. Conversely, B. infantis ATCC
15697 exhibits significantly more growth on excess fucose with
limiting concentrations of preferred carbohydrates, relative to
individual carbohydrate components. It is clear that fucose
catabolism is interconnected with the bifid shunt given the
production of end-products typically secreted by bifidobacteria.
The mechanistic relationship between the feeder fucose pathway
and the bifid shunt is yet to be fully validated. Bifidobacterial
metabolism of fucose may provide additional protection against
enteric pathogens, which are known to utilize fucose cleaved
from host mucin. Continued investigation of fucosylated
HMOs and co-fermentation of free fucose in combination
with other carbohydrate sources will enable greater clarity
in this regard. Moreover, investigating additional B. infantis
strains, as well as other species, will generalize observations
to inform in vitro and in vivo host-microbial models in an
effort to characterize metabolic networks between the infant
and its microbiota. Ultimately, the goal is to understand
this system with scientific rigor to potentially innovate
precision nutrition interventions to support infant health
and development.
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